Form 4: Avalo Therapeutics Chief Legal Officer Acquires 100,000 Stock Options

Avalo Therapeutics' Chief Legal Officer, Paul Varki, was granted 100,000 stock options on January 28, 2025.

Summary

• Paul Varki, the Chief Legal Officer of Avalo Therapeutics, Inc., was granted 100,000 stock options on January 28, 2025.
• The exercise price of these options is $8.04 per share.
• The options vest 25% on January 28, 2026, with the remaining 75% vesting in equal monthly installments over the following three years, contingent on continued service.
• The options expire on January 28, 2035.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management and shareholder interests. There are no negative implications.

Positives

• The grant of stock options to the Chief Legal Officer aligns his interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Risks

• The value of the stock options is dependent on the future performance of Avalo Therapeutics' stock price.
• If the stock price does not exceed the exercise price of $8.04, the options will have no value.

Future Outlook

The vesting schedule of the stock options is tied to the continued service of the Chief Legal Officer, suggesting a focus on long-term stability and performance.

Industry Context

Stock option grants are a common form of executive compensation in the biotechnology industry, used to incentivize performance and align management interests with shareholders.

Comparison to Industry Standards

• Stock option grants are a standard practice for executive compensation in the biotech industry.
• The vesting schedule of 25% after one year and the remainder over three years is a typical vesting structure.
• The exercise price of $8.04 will be compared to the current market price of the stock to determine the value of the options.

Stakeholder Impact

• Shareholders may view the stock option grant positively as it incentivizes the Chief Legal Officer to contribute to the company's long-term success.
• The vesting schedule encourages the Chief Legal Officer's continued service, which benefits the company.

Key Dates

Keywords

stock options, insider trading, executive compensation, Avalo Therapeutics, AVTX, Paul Varki, Chief Legal Officer